However, the second-generation MEK inhibitor binimetinib elicited similar rates of partial response, i.e. ∼20% in patients with NRAS- and BRAF-driven melanoma in a phase II clinical trial (Ascierto et al., 2013). Here, BRAF is linked to melanoma.